2002
DOI: 10.1006/clim.2001.5149
|View full text |Cite
|
Sign up to set email alerts
|

Decreased Lamina Propria Effector Cell Responsiveness to Interleukin-10 in Ileal Crohn's Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
7
0
1

Year Published

2002
2002
2006
2006

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(9 citation statements)
references
References 41 publications
1
7
0
1
Order By: Relevance
“…or s.c. administration of IL-10 to patients with active CD or ulcerative colitis gave unclear results on the therapeutic efficacy of IL-10 treatment (41)(42)(43)(44)(45)(46). Several reasons can account for the overall failure of IL-10 therapy to treat inflammatory mucosal diseases, including an inappropriate route of administration, the short serum half-life of IL-10, and its pleiotropic activities (47). The current study has important implications for an IL-10-based therapy for CD.…”
Section: Discussionmentioning
confidence: 88%
“…or s.c. administration of IL-10 to patients with active CD or ulcerative colitis gave unclear results on the therapeutic efficacy of IL-10 treatment (41)(42)(43)(44)(45)(46). Several reasons can account for the overall failure of IL-10 therapy to treat inflammatory mucosal diseases, including an inappropriate route of administration, the short serum half-life of IL-10, and its pleiotropic activities (47). The current study has important implications for an IL-10-based therapy for CD.…”
Section: Discussionmentioning
confidence: 88%
“…24 In CD patients, there does not appear to be an IL10 deficiency in the ileum or in peripheral blood. 33 In the diseased ileum, IL10 does not downregulate proinflammatory cytokines and in fact may lead to increased TNFa production. 33 The explanation for these observations is not as yet clear but may involve interleukin-12 acting synergistically with IL10 in the inflamed tissue sites, but not in normal specimens.…”
Section: Discussionmentioning
confidence: 99%
“…33 In the diseased ileum, IL10 does not downregulate proinflammatory cytokines and in fact may lead to increased TNFa production. 33 The explanation for these observations is not as yet clear but may involve interleukin-12 acting synergistically with IL10 in the inflamed tissue sites, but not in normal specimens. Alternatively, CD patients may possess an abnormality within the IL10 pathway further downstream (the IL10 receptor).…”
Section: Discussionmentioning
confidence: 99%
“…The reduction in circulating β 7 + and β 7 – IL‐10 producing T cells in Crohn's disease may be due to selective recruitment of IL‐10 producing T cells into intestinal tissue in an attempt to control inflammation. Expression of mRNA for IL‐10 has been shown to be elevated in the mucosa of IBD patients compared with healthy controls [37,38] and lymphocytes cells extracted from mucosal tissue of Crohn's disease patients produced normal levels of IL‐10 in vitro [39]. There may be defective signalling by IL‐10 rather than a lack of production and supporting this concept, cells extracted from the mucosa of IBD patients are deficient in their response to IL‐10 [39].…”
Section: Discussionmentioning
confidence: 99%